Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Quentin30on Oct 20, 2023 5:04pm
118 Views
Post# 35693878

RE:RE:RE:RE:RE:RE:RE:Keytruda+Chemo neoadjuvant in early ER+/HER2- breast cancer

RE:RE:RE:RE:RE:RE:RE:Keytruda+Chemo neoadjuvant in early ER+/HER2- breast cancerDammit, you made me laugh out loud again Azzak..!!

no-one knows what's gonna happen with this stock... nor the market...  But with wars both hot and cold ongoing, collapsing housing markets, highest bond yields in 16 years and talk of debt implosion, you could say that we're at peak despair...

But, like when making a cake, add the required amount, and sprinkle for good measure... so perhaps we really need to see some blood on the streets first, before a rebound.

ONCY will only move on solid evidence of efficacy, we still don;'t have unassailable statisical data, nor do we appear to have a partner (hence the recent financing, which is always a bad sign). The PanCan deal was supposed to have been inked a month ago. ONCY mngmt just can't ever seem to get their ducks lined up..

My big beef with Coffey, is that the mBC Ph III was delayed by Aware-1 and Bracelet-1 to save time... I always wondered why not just run the phase III, and add a cpi when you have a revenue stream... and those were pretty much his precice words after avelumad turned out to be a damp squib... that's 5 years and millions wasted. And the treatment case has moved on... I just don't think they will ever run this Ph III now... Adlai Nortye have no reason to stall... it won't happen.

We wait for Panc, that may be this company's savoing grace, and worth buying and holding stock when there is nothing but despair... price isn't there yet.
<< Previous
Bullboard Posts
Next >>